MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics operates in the Biotechnology industry of the Healthcare sector, headquartered in Zug, ZG, CH. The stock last traded at $17.16, up 3.44% on the session, giving a market capitalisation of $1.44B. On trailing twelve-month figures it carries a trailing P/E of -4.46, a net margin of 0.0%. Its beta of 1.07 implies it has historically moved more than the broad market.
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MoonLake Immunotherapeutics is most often compared with the following Healthcare names: